Veterinary Medicines

AVIPOX-GAL

Authorised
  • Fowlpox virus, strain GAL-MP1, Live
Download as PDF

Product identification

Medicine name:
AVIPOX-GAL
Active substance:
  • Fowlpox virus, strain GAL-MP1, Live
Target species:
  • Chicken
  • Pheasant
  • Turkey
Route of administration:
  • Transdermal use
  • Cutaneous use

Product details

Active substance and strength:
  • Fowlpox virus, strain GAL-MP1, Live
    100.00
    50% Embryo Infective Dose
    /
    0.01
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate for suspension for injection
Withdrawal period by route of administration:
  • Transdermal use
    • Chicken
      • Meat
        0
        day
      • Egg
        0
        day
    • Pheasant
      • Meat
        0
        day
      • Egg
        0
        day
  • Cutaneous use
    • Turkey
      • Meat
        0
        day
      • Egg
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD12
Legal status of supply:
This information is not available for this product.
Authorisation status:
  • Valid
Authorised in:
  • Romania
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Romvac Company S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Romvac Company S.A.
Responsible authority:
  • Institute For Control Of Biological Products And Veterinary Medicines
Authorisation number:
  • 120010
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Romanian (PDF)
Published on: 16/12/2021
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."